KYORIN Pharmaceutical Co.,Ltd.

As of March 31, 2026, KYORIN Pharmaceutical Co.,Ltd. carries a market capitalization of 94.50B, placing it among publicly traded companies globally. Its enterprise value stands at 103.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

KYORIN Pharmaceutical Co.,Ltd.'s next confirmed earnings release is scheduled for November 9, 2026.

As of March 31, 2026, KYORIN Pharmaceutical Co.,Ltd. has 57.45M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, KYORIN Pharmaceutical Co.,Ltd. maintains a current ratio of 4.60, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, KYORIN Pharmaceutical Co.,Ltd.'s stock has declined approximately 21.18% over the past 52 weeks. The 50-day moving average sits at 1,120.50, while the 200-day moving average is 1,370.88.

As of March 31, 2026, KYORIN Pharmaceutical Co.,Ltd. holds 15.08B in cash and equivalents against 23.79B in total debt, resulting in a net debt position of 11.52B. Total book value stands at 142.43B, with working capital of 105.77B providing operational flexibility.

KYORIN Pharmaceutical Co.,Ltd.'s most recent stock split took place on September 25, 2001 with a 2:3 split ratio.